Updated:
SD Biosensor
SD Biosensor, a South Korean in-vitro diagnostics firm, develops rapid tests for infectious diseases, cardiac markers, and pregnancy tests.
SD Biosensor
SD Biosensor is headquartered in Suwon-si, South Korea, and describes itself as a global leader in in-vitro diagnostics. The company's product line includes rapid diagnostic tests for infectious diseases such as COVID-19, influenza, and dengue, as well as cardiac markers and pregnancy tests. The company manufactures both reagents and diagnostic devices. It distributes through a network of partners across Asia, Europe, and the Americas. SD Biosensor's COVID-19 antigen test received emergency use authorization from the World Health Organization in 2021. The firm does not disclose financial data, team size, or investment activity. No principals or senior management are named on its public website. The company maintains a corporate website in Korean and English but provides limited institutional information. As a product-focused manufacturer, SD Biosensor differs from investment-oriented family offices. Its structure is that of an operating company in the medical device sector, not an asset manager. No verifiable information suggests it functions as a family office or investment vehicle.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Suwon-si
Corporate office
Suwon-si, Seoul, South Korea
Sector focus
Frequently asked questions
Does SD Biosensor function as a family office or investment firm?
No. SD Biosensor is an operating company in the in-vitro diagnostics sector. Its business is the development, manufacturing, and distribution of rapid diagnostic tests and reagents. There is no public evidence that it manages third-party capital or makes investment allocations typical of a family office.
What products does SD Biosensor manufacture?
SD Biosensor produces rapid diagnostic tests for infectious diseases (COVID-19, influenza, dengue, HIV), cardiac markers (troponin I, NT-proBNP), pregnancy tests, and a range of reagent kits. It also manufactures the handheld STANDARD Q reader device for quantitative testing.
Where does SD Biosensor operate geographically?
SD Biosensor is headquartered in Suwon-si, South Korea. Its products are distributed across Asia, Europe, and the Americas through distributors and original equipment manufacturer (OEM) arrangements. The company does not disclose specific regional revenue breakdown.
Who leads SD Biosensor?
SD Biosensor does not publicly name its CEO, management team, or board members on its website. No senior leadership information is available from the company's public channels.
Is SD Biosensor publicly traded or privately held?
SD Biosensor is privately held. It does not disclose ownership structure, shareholders, or any affiliation with a family office or investment holding company.
Was SD Biosensor involved in COVID-19 testing?
Yes. SD Biosensor's STANDARD Q COVID-19 Ag Test received emergency use authorization from the World Health Organization in 2021. In October 2023, the company announced a supply agreement with UNICEF to distribute the test to low- and middle-income countries (per company press release).
Does the company have regulatory approvals for its products?
SD Biosensor's COVID-19 antigen test has received WHO Emergency Use Listing. The company also holds CE marking for many of its diagnostic products, allowing sale in the European Union. It does not disclose FDA clearance for any of its tests.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: